Treating mucus plugs in COPD could affect mortality

Targeting mucus plugs could lower mortality from COPD, chronic obstructive pulmonary disease, the fourth leading cause of death in the United States. Researchers reported this finding on May 21, 2023 in JAMA, the Journal of the American Medical Association. The findings were also reported on the same day at the American Thoracic Society 2023 International Conference. “As a chronic disease, […]

“Long Covid” linked to disease of small airways in lungs

Researchers report that persistent disease of the small airways in the lungs, with yet unknown long-term effects, appears to be a possible log-term effect of COVID-19, and it is unrelated to initial infection severity. The findings were published on March 15, 2022 in Radiology. “For the first time, we’re describing small airways disease in this population of COVID-19 patients with […]

Standard for pulmonary function tests gets an update

In the latest update to the pulmonary function tests technical standard series, the American Thoracic Society and European Respiratory Society address the uncertainty around the interpretation of the tests which are essential in determining the extent of respiratory dysfunction. The update was recently published in the European Respiratory Journal ahead of a planned webinar series by the ATS. The update builds upon prior recommendations from the American […]

FDA grants Tentative Approval for Yutrepia to treat pulmonary arterial hypertension – Liquidia Corpn

Liquidia Corporation has announced that the FDA granted tentative approval for Yutrepia (treprostinil) inhalation powder, previously referred to as LIQ 861. Yutrepia is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. Tentative approval indicates that Yutrepia has met all regulatory standards for […]

New real-world observational analysis of Uptravi underscores the importance of risk assessment for treating pulmonary arterial hypertension patients -Johnson & Johnson

Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension (PAH) patients treated with Uptravi (selexipag)from Johnson & Johnson, either maintained (56%) or reduced (20%) their one-year mortality risk score. The SPHERE results were published in the April issue of the Journal […]